ALX Oncology Holdings Inc.

NasdaqGS:ALXO Stock Report

Market Cap: US$24.8m

ALX Oncology Holdings Balance Sheet Health

Financial Health criteria checks 4/6

ALX Oncology Holdings has a total shareholder equity of $88.3M and total debt of $10.0M, which brings its debt-to-equity ratio to 11.3%. Its total assets and total liabilities are $120.9M and $32.6M respectively.

Key information

11.29%

Debt to equity ratio

US$9.97m

Debt

Interest coverage ration/a
CashUS$97.83m
EquityUS$88.30m
Total liabilitiesUS$32.61m
Total assetsUS$120.90m

Recent financial health updates

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Mar 12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Recent updates

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 12

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27

ALX Oncology: Trying To Justify The Hype

Apr 18

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Mar 12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

ALX Oncology GAAP EPS of -$0.81 misses by $0.18

Aug 08

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

Aug 01

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

Jun 29

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Feb 15

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Nov 30

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Sep 08

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Financial Position Analysis

Short Term Liabilities: ALXO's short term assets ($102.5M) exceed its short term liabilities ($18.7M).

Long Term Liabilities: ALXO's short term assets ($102.5M) exceed its long term liabilities ($13.9M).


Debt to Equity History and Analysis

Debt Level: ALXO has more cash than its total debt.

Reducing Debt: ALXO's debt to equity ratio has increased from 5.6% to 11.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALXO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALXO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 30.1% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 22:30
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALX Oncology Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Li Wang WatsekCantor Fitzgerald & Co.
Martin AusterCredit Suisse